Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients

Table 1 Baseline characteristics of the study population

	TT group (n = 110)	CT group (n = 107)	P value
Age, mean ± SD (yr)	58.66 ± 13.03	56.67 ± 10.88	0.22
Men, n (%)	55 (50.00)	52 (48.60)	0.89
Body mass index (m2/kg)	24.31 ± 3.23	23.87 ± 2.91	0.35
Smoking, n (%)	24 (22.82)	22 (20.59)	0.74
Drinking, n (%)	30 (30.00)	28 (26.17)	0.39
Comorbidity			0.81
Hypertension, n (%)	26 (23.64)	23 (21.50)
Diabetes mellitus, n (%)	22 (20.00)	25 (23.36)
Cardiovascular disease, n (%)	2 (1.82)	2 (1.86)
Reasons for eradication			0.37
Peptic ulcer disease	49 (44.54)	43 (40.19)
Post ESD due to EGC	4 (3.63)	2 (1.87)
MALToma	0 (0.00)	1 (0.93)
Chronic atrophic gastritis with intestinal metaplasia	57 (51.82)	61 (57.01)
Clarithromycin resistance diagnosed by DPO-PCR
No, n (%)	81 (73.64)
A2142G positive, n (%)	4 (3.64)
A2143G positive, n (%)	25 (22.73)
Follow up loss, n (%)	9 (8.18)	10 (9.35)	0.95
Poor compliance, n (%)	0 (0.00)	2 (0.02)	0.30

TT: Tailored therapy; CT: Concomitant therapy; DPO-PCR: Dual priming oligonucleotide polymerase chain reaction; ESD: Endoscopic submucosal dissection; EGC: Early gastric cancer; MALToma: Mucosa associated lymphoid tissue lymphoma.

Table 2 Helicobacter pylori eradication success rates

Eradication rate	TT group (n = 110)	CT group (n = 107)	P value
Intention-to-treat	91/110 (82.73)	88/107 (82.24)	0.95
Per-protocol	91/101 (90.10)	87/951 (91.58)	0.72

¹Of 107 patients who were initially allocated into concomitant therapy group, 10 were lost to follow-up, and two patients showed poor compliance for taking medication (one patient showed eradication success, and the other eradication failure). Therefore, a total of 95 patients were included in our per-protocol analysis. TT: Tailored therapy; CT: Concomitant therapy.

Table 3 Eradication success rate in tailored therapy group according to dual priming oligonucleotide polymerase chain reaction results

Eradication rate	No mutation	A2142G positive	A2143G positive
Number of patients who initially enrolled	81	4	25
Number of patients with eradication failure	9	0	1
Number of patients lost to follow up	7	1	1
Number of patients with poor compliance	0	0	0
Eradication success rate
Intention-to-treat	65/81 (80.25%)	3/4 (75.00%)	23/25 (92.00%)
Per-protocol	65/74 (87.84%)	3/3 (100%)	23/24 (95.83%)

Table 4 Treatment related adverse events, n (%)

	TT group (n = 1011)	CT group (n = 972)	P value
Eradication related Side effects			< 0.001
No	78 (77.23)	48 (49.48)
Yes	23 (22.77)	49 (50.52)
Taste disturbance	2 (1.98)	18 (18.56)
Nausea/vomiting	10 (9.90)	15 (15.46)
Diarrhea/loose stool/constipation	6 (5.94)	9 (9.28)
Abdominal discomfort, dyspepsia	3 (2.97)	3 (3.09)
General weakness, myalgia	1 (0.99)	1 (1.03)
Dizziness, headache	1 (0.99)	2 (2.06)
Skin rash	0 (0.00)	1 (1.03)

¹Of the 110 patients who were initially allocated into the tailored therapy (TT) group, 9 were not followed up. Therefore, a total of 101 patients were included in the TT group.

²Of the 107 patients who were initially allocated into the concomitant therapy (CT) group, 10 were lost to follow up. Therefore, a total of 97 patients were included in the CT group, regardless of compliance status. TT: Tailored therapy; CT: Concomitant therapy.